Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Silo Pharma Inc (SILO)

Silo Pharma Inc (SILO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,888
  • Shares Outstanding, K 2,803
  • Annual Sales, $ 70 K
  • Annual Income, $ -3,700 K
  • 60-Month Beta -0.24
  • Price/Sales 64.15
  • Price/Cash Flow N/A
  • Price/Book 0.78
Trade SILO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +3.00%
on 10/03/24
1.1200 -8.04%
on 09/18/24
-0.1400 (-11.97%)
since 09/11/24
3-Month
0.9850 +4.57%
on 07/12/24
4.5000 -77.11%
on 07/18/24
+0.0500 (+5.10%)
since 07/11/24
52-Week
0.8410 +22.47%
on 07/09/24
4.5000 -77.11%
on 07/18/24
-0.5500 (-34.81%)
since 10/11/23

Most Recent Stories

More News
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.082 (+2.50%)
SILO : 1.0300 (+0.98%)
LLY : 932.06 (+2.35%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.9600 (+20.99%)
IMRN : 2.20 (-1.35%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 1.0300 (+0.98%)
LLY : 932.06 (+2.35%)
ACOR : 0.6610 (-24.86%)
TRVN : 1.9600 (+20.99%)
IMRN : 2.20 (-1.35%)
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

ENGLEWOOD CLIFFS, NJ – May 9,  2023 – Silo Pharma, Inc.  (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 1.0300 (+0.98%)
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc.  (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 1.0300 (+0.98%)
Silo Pharma (NASDAQ: SILO) Provides Update on Study of Ketamine Formulations for Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive...

SILO : 1.0300 (+0.98%)
Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent...

SILO : 1.0300 (+0.98%)
Silo Pharma (NASDAQ: SILO) to Benefit as Study Supports Psychedelics in Treating Depression

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than...

SILO : 1.0300 (+0.98%)
Silo Pharma (NASDAQ: SILO) Expands IP, Tech Rights for Treating Rare Stress-Related Conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15...

SILO : 1.0300 (+0.98%)
Silo Pharma (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”)...

SILO : 1.0300 (+0.98%)
Silo Pharma (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office...

SILO : 1.0300 (+0.98%)

Business Summary

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer's, and other rare neurological disorders. Silo Pharma. Inc. is based in ENGLEWOOD CLIFFS, NJ.

See More

Key Turning Points

3rd Resistance Point 1.0733
2nd Resistance Point 1.0567
1st Resistance Point 1.0433
Last Price 1.0300
1st Support Level 1.0133
2nd Support Level 0.9967
3rd Support Level 0.9833

See More

52-Week High 4.5000
Fibonacci 61.8% 3.1023
Fibonacci 50% 2.6705
Fibonacci 38.2% 2.2387
Last Price 1.0300
52-Week Low 0.8410

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar